Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
H.C. Starck is a global leader in the processing of refractory metals and advanced ceramics, providing critical materials and components to the healthcare industry. The company is a primary supplier of high-density tungsten and molybdenum used in medical imaging systems, including CT scanners and X-ray tubes, where they serve as anodes and radiation shielding. Furthermore, H.C. Starck produces high-purity tantalum and niobium, which are essential for biocompatible medical implants and various surgical applications. Over the past several years, the company has transitioned from a conglomerate into specialized entities, with its core 'Solutions' business being acquired by Materion Corporation in 2022. Their products are vital for the performance and safety of diagnostic equipment and permanent medical devices. The company maintains a strong global footprint with manufacturing and R&D facilities across Europe, North America, and Asia.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on H.C. Starck.